Meeting
2022 ASCO Annual Meeting
Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
Authors
Haibo Qiu
Sun Yat-Sen University Cancer Center, Guangzhou, China
Haibo Qiu , Zhiwei Zhou , Ye Zhou , XiangBin Wan , Kaixiong Tao , Yong Li , Xin Wu , Lihui Liu , Zi Chen , Lichuang Men , ZHIYAN LIANG , Ming Lu , Lixin Jiang , Dajun Yang , Rui-hua Xu , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT03594422
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11513)
DOI
10.1200/JCO.2022.40.16_suppl.11513
Abstract #
11513
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Inhibition of autophagy sensitizes gastrointestinal stromal tumor cells to TKI/Bcl-2 inhibitors-induced apoptosis.
First Author: Shuchao Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
First Author: Suzanne George
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne